Indication
HER2-positive
7 clinical trials
10 products
1 drug
Product
CT-0508Clinical trial
A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-omburtamab for Neuroblastoma Central Nervous System/Leptomeningeal MetastasesStatus: Terminated, Estimated PCD: 2023-06-02
Product
PembrolizumabProduct
RC48-ADCClinical trial
A Single-arm, Multicentre, Open Phase Ⅱa Clinical Study of RC48-ADC in the Treatment of HER2 Variant (Mutation, Amplification, Overexpression) Advanced MelanomaStatus: Recruiting, Estimated PCD: 2024-12-30
Product
AZD5363Clinical trial
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 Under Adaptable Dosing Schedules in Patients With Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2019-04-26
Clinical trial
A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2Status: Recruiting, Estimated PCD: 2027-04-01
Product
XMT-2056Clinical trial
An Open-Label, Single-Arm Study of Autologous Anti-HER2 Chimeric Antigen Receptor Monocytes (CT-0525), in Participants With HER2 Over Expressing Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-31
Product
CT-0525Clinical trial
Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 StudyStatus: Active (not recruiting), Estimated PCD: 2018-12-01
Product
PTC+PertuzumabProduct
FEC-T+PertuzumabClinical trial
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)Status: Active (not recruiting), Estimated PCD: 2024-12-29
Product
ZanidatamabProduct
LetrozoleDrug
Tamoxifen